IL174935A - T cell vaccine for treating multiple sclerosis and method of making same - Google Patents
T cell vaccine for treating multiple sclerosis and method of making sameInfo
- Publication number
- IL174935A IL174935A IL174935A IL17493506A IL174935A IL 174935 A IL174935 A IL 174935A IL 174935 A IL174935 A IL 174935A IL 17493506 A IL17493506 A IL 17493506A IL 174935 A IL174935 A IL 174935A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- mbp
- fragment
- autologous
- seq
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 119
- 201000006417 multiple sclerosis Diseases 0.000 title claims description 74
- 229940030156 cell vaccine Drugs 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 77
- 102000047918 Myelin Basic Human genes 0.000 claims description 68
- 101710107068 Myelin basic protein Proteins 0.000 claims description 67
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims description 9
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 7
- 102000016202 Proteolipids Human genes 0.000 claims description 5
- 108010010974 Proteolipids Proteins 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003226 mitogen Substances 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- -1 PLP Proteins 0.000 claims 2
- 108010047620 Phytohemagglutinins Proteins 0.000 claims 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 claims 1
- 230000001885 phytohemagglutinin Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 80
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 49
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 22
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 20
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 19
- 230000001472 cytotoxic effect Effects 0.000 description 18
- 230000003013 cytotoxicity Effects 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 14
- 108091054437 MHC class I family Proteins 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 208000016192 Demyelinating disease Diseases 0.000 description 8
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 8
- 102000006386 Myelin Proteins Human genes 0.000 description 8
- 108010083674 Myelin Proteins Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000004248 oligodendroglia Anatomy 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 206010012305 Demyelination Diseases 0.000 description 7
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 201000002491 encephalomyelitis Diseases 0.000 description 7
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 102000054064 human MBP Human genes 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000000779 depleting effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100400614 Homo sapiens MBP gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 101710110798 Mannose-binding protein C Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 241001483952 Peach chlorotic mottle virus Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102100029513 Ubiquinol-cytochrome-c reductase complex assembly factor 2 Human genes 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
- A61K40/453—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51221203P | 2003-10-17 | 2003-10-17 | |
| PCT/US2004/034448 WO2005037309A1 (en) | 2003-10-17 | 2004-10-18 | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL174935A0 IL174935A0 (en) | 2006-08-20 |
| IL174935A true IL174935A (en) | 2012-01-31 |
Family
ID=34465326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL174935A IL174935A (en) | 2003-10-17 | 2006-04-11 | T cell vaccine for treating multiple sclerosis and method of making same |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20080107664A1 (enExample) |
| EP (1) | EP1677821B1 (enExample) |
| JP (1) | JP2007509063A (enExample) |
| CN (1) | CN1893971A (enExample) |
| AU (1) | AU2004281817B2 (enExample) |
| BR (1) | BRPI0415519A (enExample) |
| CA (1) | CA2542668C (enExample) |
| IL (1) | IL174935A (enExample) |
| NZ (1) | NZ546552A (enExample) |
| WO (1) | WO2005037309A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004281817B2 (en) * | 2003-10-17 | 2010-07-22 | Baylor College Of Medicine | A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis |
| ES2552667T3 (es) * | 2006-05-05 | 2015-12-01 | Opexa Therapeutics | Vacuna de células T |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| AU2010319323B2 (en) * | 2009-11-14 | 2015-01-15 | Cardiovax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| RU2435556C1 (ru) * | 2010-04-23 | 2011-12-10 | Владимир Васильевич Лантух | Способ лечения дистрофических заболеваний заднего полюса глаза |
| WO2013063713A1 (zh) * | 2011-10-31 | 2013-05-10 | 鑫品生医科技股份有限公司 | 诱发产生综合免疫细胞的方法 |
| CN105085616A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种氨基酸序列及其应用 |
| CN105085615A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种多肽序列及其应用 |
| EP3570852B1 (en) * | 2017-01-20 | 2025-07-30 | Atara Biotherapeutics, Inc. | Autologous cytotoxic t cells (ctls) expressing an ebv-binding t cell receptor for use in treating or preventing primary progressive multiple sclerosis (ms) or secondary progressive ms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3434510B2 (ja) | 1992-04-09 | 2003-08-11 | オートイミューン インク | ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制 |
| US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US20020042423A1 (en) | 1998-04-29 | 2002-04-11 | John R. Richert | Methods for identifying compounds that bind to hla molecules and use of such compounds as hla-agonists or antagonists |
| AU2002308732A1 (en) * | 2001-05-15 | 2002-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| AU2004281817B2 (en) * | 2003-10-17 | 2010-07-22 | Baylor College Of Medicine | A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis |
-
2004
- 2004-10-18 AU AU2004281817A patent/AU2004281817B2/en not_active Ceased
- 2004-10-18 BR BRPI0415519-0A patent/BRPI0415519A/pt not_active Application Discontinuation
- 2004-10-18 JP JP2006535420A patent/JP2007509063A/ja active Pending
- 2004-10-18 WO PCT/US2004/034448 patent/WO2005037309A1/en not_active Ceased
- 2004-10-18 EP EP04795590A patent/EP1677821B1/en not_active Expired - Lifetime
- 2004-10-18 CA CA2542668A patent/CA2542668C/en not_active Expired - Fee Related
- 2004-10-18 US US10/575,831 patent/US20080107664A1/en not_active Abandoned
- 2004-10-18 CN CNA2004800372329A patent/CN1893971A/zh active Pending
- 2004-10-18 NZ NZ546552A patent/NZ546552A/en not_active IP Right Cessation
-
2006
- 2006-04-11 IL IL174935A patent/IL174935A/en not_active IP Right Cessation
-
2009
- 2009-12-03 US US12/630,228 patent/US20100183546A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2542668A1 (en) | 2005-04-28 |
| CA2542668C (en) | 2014-04-29 |
| WO2005037309A1 (en) | 2005-04-28 |
| EP1677821B1 (en) | 2013-02-27 |
| CN1893971A (zh) | 2007-01-10 |
| BRPI0415519A (pt) | 2006-12-26 |
| NZ546552A (en) | 2009-10-30 |
| JP2007509063A (ja) | 2007-04-12 |
| IL174935A0 (en) | 2006-08-20 |
| EP1677821A1 (en) | 2006-07-12 |
| AU2004281817A1 (en) | 2005-04-28 |
| US20100183546A1 (en) | 2010-07-22 |
| AU2004281817B2 (en) | 2010-07-22 |
| US20080107664A1 (en) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zang et al. | Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis | |
| EP1812563B1 (en) | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use | |
| US20100183546A1 (en) | Method for Increasing CD8+ Cytotoxic T Cell Responses and for Treating Multiple Sclerosis | |
| Salvetti et al. | T-lymphocyte reactivity to the recombinant mycobacterial 65-and 70-kDa heat shock proteins in multiple sclerosis | |
| JP2010252806A (ja) | 同種抗原の特定方法、ならびに癌治療および移植へのその使用 | |
| CN108291203A (zh) | Cd8+cd45rc低treg的新亚群及其用途 | |
| US7972848B2 (en) | Isolation and identification of cross-reactive T cells | |
| JP6000205B2 (ja) | Ｔ細胞ワクチン | |
| Herzog et al. | Increased in vivo frequency of IA-2 peptide-reactive IFNγ+/IL-4− T cells in type 1 diabetic subjects | |
| WO2008028229A1 (en) | Methods of identifying markers | |
| WO2022253957A1 (en) | Person-tailored t cell composition targeting merkel cell carcinoma | |
| Hooper et al. | Spleen cells from antigen‐minimized mice are superior to spleen cells from germ‐free and conventional mice in the stimulation of primary in vitro proliferative responses to nominal antigens | |
| US20220362358A1 (en) | Bacteria-engineered to elicit antigen-specific t-cells | |
| HK1102914A (en) | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis | |
| RU2766691C9 (ru) | НОВАЯ СУБПОПУЛЯЦИЯ CD8+CD45RClow КЛЕТОК TREG И ЕЕ ПРИМЕНЕНИЯ | |
| WO2025128638A1 (en) | Cow milk allergen epitopes, megapools and uses thereof | |
| Backer | Epithelial cells: an immune modulator in the context of inflammatory bowel diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |